Innovent Biologics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Innovent Biologics, Inc.
Four latecomers including Akeso and Henlius managed to record a combined $101m in immuno-oncology drug sales in China in the first half, while market leaders such as BeiGene and Innovent saw mixed results as competition between domestically-developed rivals continues to heat up.
The Chinese company's R&D leader discusses the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.
The Chinese company's R&D leader talked to Scrip about the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.
Sorrento plans to meet with the US FDA regarding abivertinib, but the agency’s tough stance on drug approvals based on single-country studies could thwart the company’s efforts.
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Innovent Biologics (Suzhou) Co., Ltd.